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Summary.-Viable cultured oat-cell carcinoma cells were used to immunize a goat.
The resulting antiserum contained high titres of anti-normal activity and anti-
bodies to CEA. It was also shown, by indirect immunofluorescence, using fluorescein-
conjugated rabbit anti-goat Ig, to localize at high titres on the surface membranes
of human lung cancer cells of 4 different histological types. Booster immunizations
produced a maximum secondary response one week after 2 weekly injections.
The course of each immunization has been monitored for activity against normal
human tissues, and the final sera have been absorbed with human spleen cells to
remove anti-normal activity. Cross-reactivity with the lung-cancer-cell panel and
antibodies to CEA persisted in high titre after absorption of anti-normal antibodies,
and were present in the ammonium-sulphate-precipitated globulin fraction.
The cells used for immunization did not produce detectable amounts of CEA in
culture, and were not known to contain CEA prior to this experiment. Removal of
anti-CEA antibodies by absorption with purified CEA has not reduced the cross-
reactivity of the absorbed antiserum with the panel of human lung-cancer cells.
HUMAN lung tumours produce tumour-
associated macromolecules which can be
identified in patients' sera (Vincent and
Chu, 1973) and which, in some individuals,
are valuable as serum markers indicating
disease status (Newman et al., 1976; Ford,
Newman and Lakin, 1977). Derepressed
gene products of tumour cells (e.g. differ-
entiation antigens, hormones and foetal
proteins) are unlikely to be immunogenic
in the human tumour-bearing host, who
will have already developed immunological
tolerance of them during foetal life. Other
tumour-associated antigens not detected
during foetal development have also been
described (Hollinshead and Stewart, 1977).
Xenoantisera contain antibodies to lung-
tumour antigens as well as to "normal"
antigens (Viza et al., 1975; Frost, Rogers
and Bagshawe, 1975; Bell and Seetharam,
1976; Newman et al., 1977b). These anti-
sera, after removal of anti-normal anti-
bodies by absorption with normal-tissue
preparations, can be used to identify
tumour antigens, and in therapeutic
attempts to improve the poor prognosis in
advanced malignant melanoma (Everall
et al., 1977) and after resection of lung
cancer (Newman et al., 1977a). We have
previously found a high degree of cross-
reactivity between absorbed lung-cancer
antisera and lung-tumour substrates in an
indirect immunofluorescence test (New-
man et al., 1977b). We now report the use
of an established tumour cell line for the
production of cross-reacting anti-tumour
sera. The antiserum described here has a
high titre of activity against CEA, and
after removal of this, the absorbed anti-
serum reacts with the 4 major histological
types of lung tumour in an indirect
immunofluorescence test.
MATERIALS AND METHODS
The cell line (OCCI) was established in
continuous culture by Dr Morag Ellison from
biopsy material from a patient with an oat-ANTISERUM TO HUMAN OAT-CELL CARCINOMA
cell carcinoma of the bronchus. It is now,
grown in our laboratory as a suspension
culture at 37°C in 75 cm2 Falcon flasks. The
medium consists of 450o Dulbecco-Eagles
(Gibco Bio-Cult), 45%o Medium 199 with
Hanks, Hepes (20 mm) and L-glutamine, and
is supplemented wvith 10°/ lambs' serum.
100 ,ug/ml kanamycin and 1-25 AAg/ml ampho-
tericin B are also added. All cultures are
gassed with 5%0 CO2. When sufficient cell
numbers were achieved for the entire immu-
nization schedule, cells wvere disaggregated
with trypsin and versene for 1 h, resuspen-
ded in medium and kept at 37°C for 24 h to
allow recovery before freezing down and
storage in liquid N2.
Freezing and recovery of cells. The cells,
at passage number 32, were resuspended at a
concentration of 6 x 106/ml in medium con-
taining 20% lambs' serum and 10% glycerol.
Cooled samples AAere frozen at 1°C/min in a
Linde BF-4 programmable freezer (Union
Carbide Co., Los Angeles, California) to
-50°C and then fast frozen to -100°C.
Samnples were stored in liquid N2 until use,
wvhen they were thawed by immersion in a
37°C water bath, diluted with sterile inject-
able saline at the same temperature and
washed twice with saline.
Before freezing, the viability of the cells as
(letermined by phase contrast microscopy
and trypan-blue exclusion wvas 70-80%. On
resuscitation there was a drop in viability
of 500 wvith a recovery of initial cell numbers
always >85%.
Antiserumn production.-The schedule used
wvas a modification of the inethod of Ghose et
(Il. (1975).
Primary Immunization.-107 tumour cells
in 1 ml sterile saline, mixed by shaking with
1 ml Freund's complete adjuvant (FCA) wvere
injected i.m. into one flank of the goat. This
was repeated at weekly intervals for the next
3 Aweeks, using alternate limbs. Six further
immunizations were given at biweekly inter-
vals, the last 4 being of tumour-cell suspen-
sionalone, divided betweeneach ofthe4limbs.
At Day 43, 500 ml of blood was taken (B6).
Booster Immunization. On Day 1 the
animal was injected i.m. into all 4 limbs with
tumour cells mixed with FCA as above. On
Days 8 and 15, injections of tumour cells
alone were given, and on Day 29 a second
tumour-cell+adjuvant injection was given.
On Day 37, 500 ml of blood (B13) wvas
taken.
Test bleeds.-20 ml pre-immunization blood
samples were obtained and test bleeds taken
at weekly intervals throughout the schedule.
All sera were heat-inactivated (56°C for 30
min).
Serum absorption and y-globulin precipita-
tion.-B6 and B13 were absorbed x 3 with
washed human cadaver spleens using 150 g/
190 ml serum. The sera were then fractionated
by double ammonium sulphate precipitation
(Newman et al., 1977a). Antibodies to CEA
were removed from an aliquot ofB6 serum by
absorption of a 1/1000 dilution with pure
CEA by Dr Eadie Heyderman, at the
Chester Beattie Research Institute. After
absorption, the serum was negative when
tested for anti-CEA by radioimmunoassay,
and failed to show any fixation to a CEA-
containing colonic carcinoma in an immuno-
peroxidase assay.
Monitoring of inmnunizations and absorp-
tions.-All serum samples were tested for
haemolytic and haemagglutinating activity
against normal human red cells. Micro-plate-
let complement-fixations tests were performed
by the method of Colombani et al. (1972)
and micro-lymphocytotoxic tests by a modi-
fication of the method of Amos et al.
(1969).
The serum-protein patterns of B6 and B13
before and after absorption, and after Ig
precipitation, were determined by agarose-
gel electrophoresis as described by Johans-
son (1972).
Immunofiuorescence staining.
Tissue blocks taken from fresh surgical
specimens were snap-frozen and then stored
in liquid N2. Wrells were prepared by placing
8 drops of glycerol on to a 1" x 3" slide and
spraying with "Fluoroglide" PTFE (Fisons).
The glycerol drops were then washed off,
leaving, wells. Tissue blocks were cut into
5 yum sections on a cryostat and placed either
in the wells or on ordinary 1" x 3" slides for
histological examination. All sections were air
dried with warm air for 20 min and cold air
for 10 min. Those for histology were stained
using a routine haematoxylin and eosin
method.
Serial dilutions of test antisera (goat anti-
human), absorbed sera or Igs were applied to
the wells. After 20 min incubation at room
temperature (all subsequent procedures were
carried out at room temperature) slides were
washed for 10-20 min in a PBS bath with a
magnetic stirrer.
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Fluorescein-isothiocyanate-conjugated rab-
bit anti-goat y-globulin (Kallestad) was
diluted with a 1/200 dilution of rhodamine
as a counterstain. The dilution of conjugate
used was determined previously by titration
with goat Ig, and in this study was 1/10.
Before use, diluted conjugate was centri-
fuged at 3000 g for 5 min to remove aggre-
gates. The supernatant was added to the
sections followed by a 20 min incubation.
Sections wvere washed for 10 min in a PBS
bath, mounted in glycerol, a coverslip applied
and they were then examined for fluorescence.
In control wells, sections were incubated
with one of the following instead of the test
serum or Ig:
(1) PBS: a negative control to ensure no non-
specific localization of conjugate.
(2) Normal goat serum: a positive fluores-
cence control to ensure that the conjugate
reacts with goat globulin.
(3) igs from sera raised to a mycosis fungoides
tumour and to gastric cancers, absorbed and
fractionated in the same way as the anti-oat-
cell sera: the specificity controls.
Microscopy.-Microscopy was carried out
with a Reichert Zetopan microscope using
transmitted light from a mercury-vapour
lamp (HBO 200). The system incorporates a
fluorescein-isothiocyanate blue exciter filter,
widefield immersion darkground condenser,
wide aperture x 40 objective and blue
barrier filter. When UV light was used to
observe sections, UV exciter and barrier filters
were used. Photographs of representative
sections were taken with a Vickers camera
and photometer using Agfachrome 50L
professional film.
Assay of anti-CEA activity.-Activity was
measured by radioimmunoassay by a modifi-
cation of the method of Egan et al. (1972). To
determine the CEA-binding capacity of the
serum, serial dilutions were reacted with MRC
standard125I-labelled CEA. Antigen-antibody
complexes formed were collected by poly-
ethyleneglycol precipitation. Appropriate ser-
um dilutions were then compared with
standard anti-CEA sera in inhibition tests
using competing unlabelled CEA.
RESULTS
Immanization procedure
The reactivity of the xenogeneic anti-
sera against normal human cells, through-
out the course ofimmunization, is illustra-
ted in Fig. 1. The largest increases occur
in the complement-mediated lymphocyto-
toxic test, with haemagglutinating and
haemolytic activity increasing in parallel.
The hyperimmune serum (B13) shows
slightly lower activity with less variation
in titres at each test bleed. The optimal
boosting schedule appears to be 2 injec-
tions of tumour cells at weekly intervals,
followed by collection of blood on Day 14.
Reduction of antibody activity against
normal human antigens
Antisera absorbed sequentially with
human cadaver spleen cells showed rapid
reduction in anti-normal-human-cell anti-
body titre (Fig. 2) with no concurrent
reduction in anti-tumour immunofluores-
cent activity. The level ofplatelet comple-
ment-fixing activity was not reduced by
the second and third absorptions. Ammo-
nium sulphate fractionation had little
effect on the residual anti-normal titre,
but the y-globulin recovery from the B6
serum was only 20-30%, and this is
reflected later in the reduced specific
anti-tumour-cell activity.
Demonstration ofc}0oss-reacting anti-tumour
activity
(1) Immunofluorescence studies.-In
these studies, sections from 4 histologically
different types of lung tumour were in-
vestigated. The histology was confirmed
by Dr C. Edwards, Department of Patho-
logy, East Birmingham Hospital. Specific
tumour-cell staining of such sections was
seen as bright linear fluorescence out-
lining the tumour cells. These cells could
be clearly identified, and were always seen
in adjacent sections stained with H and E.
Cytoplasmic staining of normal lung
parenchyma and bronchial epithelial cells,
regarded as non-specific, was always
diffuse, with dull fluorescence and no
detectable cell-membrane staining. The
titre of the antiserum is recorded as the
highest dilution giving specific tumour-
cell-membrane staining. At these titres,
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TABLE I.-Imrnunofluorescence Titres of
Cell - membrane - localizing Antibodies
against a Cell Panel Including 4 Differ-
ent Histological Lung Tumour Types
Anaplastic I.
2.
Squamous Cell* 1.
2.
Oat Cell 1.
2.
Adeno ca 1.
2.
TIMNE (DA3S
FIG. 1 -Anti-normal activity of sera during
primary and booster immunizations.
A lymphocytotoxicity. * *
Haemagglutinating activity. 0
Haemolytic activity. 0 0 Anti-
platelet complement-fixing activity.
3. 0-
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FIG. 2. Reduction of anti-normal activity
during absorptions with human spleen
cells. A Lymphocytotoxicity.
* -* Haemagglutinating activity.
* Haemolytic activity. O O
Anti-platelet complement-fixing activity.
the non-specific cytoplasmic fluorescence
was usually undetectable. The type of
immunofluorescent staining seen with Igs
prepared to a mycosis fungoides tumour
and to gastric tumours was non-specific
and cytoplasmic when it did occur. PBS
controls were alwavs negative. Table I
shows results from these studies using the
initial serum (B6S) and the Ig prepared
from it (B61g) and the "hyperimmune"
serum (B13S) and Ig (BI31g). The results
obtainedwith each serum preparation show
a high degree ofcross-reactivity and a high-
titre anti-tumour antibody in each case.
The absorbed antisera also contained cell-
51
* Poorly differentiated, non-keratinizing.
NT =not tested
membrane-localizing antibodies to the
original immunizing cells (OCCI) and to
foetal lung epithelial cells.
(2) Anti-CEA Activity. 500o binding
of 1251-labelled MRC standard CEA
occurred at an antibody dilution of
'..1:105 in the absorbed B6 serum and
1:4000 in the fractionated Ig. The B6
absorbed antiserum at a dilution of
1: 20,000 gave an inhibition curve parallel
to that obtained with a standard anti-CEA
serum at a dilution of 1: 3000 (Fig. 3).
The culture medium from OCCI cells,
when tested in a CEA assay, gave no
detectable level ofsecreted CEA. However,
these results demonstrate clearly that the
antiserum raised to OCCI cells, has a high
titre of anti-CEA activity.
After removal of anti-CEA antibodies
from the B6 absorbed serum at a dilution
of 1: 1000, there was nosignificantfall inthe
I,00
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20
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u 5. IX 11 1~11 I IO
-
CEA nq ml
25 250
FIG. 3. Percentage inhibition of CEA
binding by B6 absorbed serum (0 0)
at a dilution of 1: 20,000, and by standard
anti-CEA serum (* *) at a dilution
of 1: 3000.
B6S
1/1,200
1/600
1/1,200
1/1,200
1/2,400
1/600
1/1,200
1/1,200
B6Ig
1/80
1/80
1/40
1/80
1/40
1/40
1/40
1/40
B13S
1/80
NT
1/32
NT
NT
1/40
1/80
NT
B13Ig
1/40
NT
1/32
NT
NT
1/40
1/40
NT
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titre ofanti-l
indirect imi
except agai]
squamous t-
of cell-meml
observed, bi
sidered clear
TABLE II.
B6 Absoi
after remoo
B61g
Proteill
mg/ml
Anti-CEA
titre
Immuno-
fluorescent
titre
Anaplastic
Oat cell
Adeno ca
Squamous
cell
* Only tested
Tumour (
antigens whi
cells, and an
of tumour ce
antibodies. I
of tumour-s-
antigens mu,
extensive ab,
carried out X
cell-membrar
prepare anti,
washed, hum
spleens remo-
high-titre ar
The anti-plat
in a compler
cal, in that
titre after t:
repeated afte
serum. This E
be present tc
one susceptib
tumour antibodies detected by to absorption with spleen cells. Alterna-
munofluorescence (Table II) tively, a difference in avidity of the anti-
nst the poorly differentiated platelet antibodies for spleen-cell antigens
umour where some evidence would explain these findings.
brane-localized antibody was The antibody response to immunization
ut was too weak to be con- with antigen extracts may vary immensely
ly positive. with the purity ofthe antigen preparation.
Some purified extracts have proved to be
-Jmmunoftuorescence Titres of only weakly immunogenic, whereas whole
rbed Antiserum (before and cells cause a more powerful but less specific
val of anti-CEA activity) and response. These oat-cell tumour cells pro-
duce little if any CEA during growth in
B6 culture, and it is extremely difficult to
B6 Spleen- B6 demonstrate CEA within the cell mem-
Spleen- an(d CEA- Spleen- brane. The very high titres of anti-CEA Absoirbedl Absorbe(d Absorbed
Serum Serum Ig antibodies were therefore unexpected.
30 30 18 Similarly, the titres of cross-reacting
1/100,000 Negative 1/4000 antibodies seen to be localising at lung- 1/4,00 tumour cell membranes were higher than
we usually find in antisera prepared using
tumour cells from surgical specimens after
1/1,200 1/1,000 1/80 storage at 20°C. This does not seem to
1/2,400 1/2,000 1/40 be due to a fortuitous immunization of a
1/1,200 1/1,000 1/40 1/1,200 /40 highly reactive animal, as non-specific
anti-normal antibodies were present in
at 31,000 dilution, Negative. titres which did not differ significantly from levels in antisera prepared in other
DISCUSSION ways. It is possible that the live cells
presented surface neoantigens in a more
cells express cell-membrane highly immunogenic configuration than
ich will be found on normal other methods, or that duration of expo-
tisera raised to pure cultures sure of these antigens within the goat was
lls will contain "anti-normal" more prolonged when living cells were
Any serological investigation used. CEA-producing tumour cells in cul-
pecific or tumour-associated ture areknown to varyin antigen secretion,
st take account of this, and the quantities produced sometimes rising
sorptions of antisera must be dramatically under unfavourable culture
with normal tissues if cells or conditions. A similar response may have
ne preparations are used to occurred in these cells during and after
sera. We have used packed, storage and immunization.
ian spleen cells prepared from The titres of cross-reacting anti-lung-
ved at postmortem to remove cancer-cell antibodies were not altered
itibodies to normal tissues. during absorption with normal tissues
elet activity ofB6S and B 13S and are unlikely to have been raised
nent-fixation test was atypi- against antigens also present on human
the substantial reduction in spleen cells. Since removal of anti-CEA
he first absorption was not antibodies also failed to remove this
r further absorptions of each activity, the antigen responsible is not
suggests that antibodies may CEA. This evidence suggests the presence
) at least 2 platelet antigens, on the cultured OCCI cells and snap-
le to and the other refractory frozen tumour suibstrates prepared from
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surgically resected specimens, of an anti-
gen not present on normal spleen cells and
not cross-reacting with CEA. Although
the interpretation of indirect immuno-
fluorescence is sometimes difficult, and the
use of positive and negative controls
mandatory, we have not seen any com-
parable levels or types of cell-membrane
fluorescence with absorbed Igs prepared
against other types of tumour or against
normal tissues. Cytoplasmic fluorescence
is usually present, at lower titres, against
most cells including tumour cells. Cell-
membrane fluorescence seen at much lower
titres against some normal tissues was
expected, as total absorption of all anti-
normal antibodies in the screening tests
against red cells, lymphocytes and plate-
lets had not been achieved. In other
experiments we have used extracts of
other tissues, including kidney, bronchus
and normal lung for absorption but have
failed to remove the antibody to the
tumour-cell-membrane antigens, even
when the antiserum has no anti-normal
activity against the tissue used for absorp-
tion. Thus, although it is possible that a
dense expression of "normal" antigen on
the membrane of the tumour cell might
localise, in very high concentration, an
anti-normal antibody, it seems more likely
that the anti-tumour antibody has been
raised against an antigen immunologically
specific to the lung-cancer cells removed at
operation and not lost during in vitro
culture of an established cell line in the
laboratory. In this context it would be
interesting to delineate the relationship
of this antigen to the inhibitory, tumour-
associated and Herpes simplex virus
antigens described by Hollinshead and
Stewart (1977).
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